Article: article from journal or magazin.
Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: a prospective double-blind study. J5 study Group.
Journal of Infectious Diseases
To evaluate the efficacy of anti-J5 serum in the treatment of severe infectious purpura, 73 children were randomized to receive either anti-J5 (40) or control (33) plasma. Age, blood pressure, and biologic risk factors were similar in both groups. At admission, however, tumor necrosis factor serum concentrations were 974 +/- 173 pg/ml compared with 473 +/- 85 pg/ml (P = .023) and interleukin-6 serum concentrations were 129 +/- 45 compared with 19 +/- 5 ng/ml (P = .005) in the control and treated groups, respectively. The duration of shock and the occurrence of complications were similar in both groups. The mortality rate was 36% in the control group and 25% in the treated group (P = .317; odds ratio, 0.76; 95% confidence interval, 0.46-1.26). This trend disappeared after correction for unbalances in risk factors at randomization using a logistic regression model. These results suggest that anti-j5 plasma did not affect the course or mortality of severe infectious purpura in children.
Bacterial Infections/complications, Bacterial Infections/therapy, Blood Pressure, Child, Child, Preschool, Double-Blind Method, Escherichia coli/immunology, Fibrinogen/analysis, Haemophilus Infections/therapy, Haemophilus influenzae, Humans, Immunization, Passive, Interleukin-6/blood, Meningococcal Infections/therapy, Prospective Studies, Purpura/complications, Purpura/therapy, Regression Analysis, Risk Factors, Tumor Necrosis Factor-alpha/analysis
Last modification date